Tags

Type your tag names separated by a space and hit enter

Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study.
J Am Coll Cardiol. 2009 Oct 06; 54(15):1467-75.JACC

Abstract

OBJECTIVES

The purpose of this study was to assess the ability of plasma B-type natriuretic peptide (BNP) to diagnose significant cardiovascular disease (CVD) in the pediatric population.

BACKGROUND

BNP has been shown to be reliable in detecting ventricular dysfunction and heart failure in adults. Timely and accurate identification of significant pediatric heart disease is important but challenging. A simple blood test could aid the front-line physician in this task.

METHODS

Subjects without a history of heart disease with findings possibly attributable to significant CVD in the acute care setting requiring a cardiology consult were enrolled. Clinicians were blinded to the BNP result, and confirmation of disease was made by cardiology consultation.

RESULTS

Subjects were divided into a neonatal (n = 42, 0 to 7 days) and older age group (n = 58, >7 days to 19 years). CVD was present in 74% of neonates and 53% of the older age group. In neonates with disease, median BNP was 526 pg/ml versus 96 pg/ml (p < 0.001) for those without disease. In older children with disease, median BNP was 122 pg/ml versus 22 pg/ml in those without disease (p < 0.001). Subjects with disease from an anatomic defect, a longer hospital stay, or who died had higher BNP. A BNP of 170 pg/ml yielded a sensitivity of 94% and specificity of 73% in the neonatal group and 87% and 70% in the older age group, respectively, using a BNP of 41 pg/ml.

CONCLUSIONS

BNP is a reliable test to diagnose significant structural or functional CVD in children. Optimal cutoff values are different from adult values.

Authors+Show Affiliations

Pediatric Cardiology, Department of Pediatrics, Children's Hospital and Regional Medical Center, University of Washington, Seattle, Washington 98105, USA. yuk.law@seattlechildrens.orgNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19796740

Citation

Law, Yuk M., et al. "Accuracy of Plasma B-type Natriuretic Peptide to Diagnose Significant Cardiovascular Disease in Children: the Better Not Pout Children! Study." Journal of the American College of Cardiology, vol. 54, no. 15, 2009, pp. 1467-75.
Law YM, Hoyer AW, Reller MD, et al. Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study. J Am Coll Cardiol. 2009;54(15):1467-75.
Law, Y. M., Hoyer, A. W., Reller, M. D., & Silberbach, M. (2009). Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study. Journal of the American College of Cardiology, 54(15), 1467-75. https://doi.org/10.1016/j.jacc.2009.06.020
Law YM, et al. Accuracy of Plasma B-type Natriuretic Peptide to Diagnose Significant Cardiovascular Disease in Children: the Better Not Pout Children! Study. J Am Coll Cardiol. 2009 Oct 6;54(15):1467-75. PubMed PMID: 19796740.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Accuracy of plasma B-type natriuretic peptide to diagnose significant cardiovascular disease in children: the Better Not Pout Children! Study. AU - Law,Yuk M, AU - Hoyer,Andrew W, AU - Reller,Mark D, AU - Silberbach,Michael, PY - 2008/12/16/received PY - 2009/05/13/revised PY - 2009/06/02/accepted PY - 2009/10/3/entrez PY - 2009/10/3/pubmed PY - 2009/10/30/medline SP - 1467 EP - 75 JF - Journal of the American College of Cardiology JO - J. Am. Coll. Cardiol. VL - 54 IS - 15 N2 - OBJECTIVES: The purpose of this study was to assess the ability of plasma B-type natriuretic peptide (BNP) to diagnose significant cardiovascular disease (CVD) in the pediatric population. BACKGROUND: BNP has been shown to be reliable in detecting ventricular dysfunction and heart failure in adults. Timely and accurate identification of significant pediatric heart disease is important but challenging. A simple blood test could aid the front-line physician in this task. METHODS: Subjects without a history of heart disease with findings possibly attributable to significant CVD in the acute care setting requiring a cardiology consult were enrolled. Clinicians were blinded to the BNP result, and confirmation of disease was made by cardiology consultation. RESULTS: Subjects were divided into a neonatal (n = 42, 0 to 7 days) and older age group (n = 58, >7 days to 19 years). CVD was present in 74% of neonates and 53% of the older age group. In neonates with disease, median BNP was 526 pg/ml versus 96 pg/ml (p < 0.001) for those without disease. In older children with disease, median BNP was 122 pg/ml versus 22 pg/ml in those without disease (p < 0.001). Subjects with disease from an anatomic defect, a longer hospital stay, or who died had higher BNP. A BNP of 170 pg/ml yielded a sensitivity of 94% and specificity of 73% in the neonatal group and 87% and 70% in the older age group, respectively, using a BNP of 41 pg/ml. CONCLUSIONS: BNP is a reliable test to diagnose significant structural or functional CVD in children. Optimal cutoff values are different from adult values. SN - 1558-3597 UR - https://www.unboundmedicine.com/medline/citation/19796740/Accuracy_of_plasma_B_type_natriuretic_peptide_to_diagnose_significant_cardiovascular_disease_in_children:_the_Better_Not_Pout_Children_Study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0735-1097(09)02361-4 DB - PRIME DP - Unbound Medicine ER -